KRAS and breast cancer: To determine the impact of miRNAs on cancer pathways, we perturbed the basal-like breast cancer cell line MDA-MB-231 (KRAS G13D, BRAF G464V, TP53 R280K and CDKN2A frameshift mutations) with 879 exogenous miRNA mimics and changes in protein levels were measured by RPPA.